EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects



Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects



Aids Research and Human Retroviruses 20(12): 1283-1288



The influence of previous structured treatment interruptions (STIs) on the length of time off therapy when highly active antiretroviral treatment (HAART) is discontinued in chronically HIV-infected subjects was assessed. A comparative, retrospective clinical cohort study included patients with plasma viral load (VL) 50 copies/ml and CD4 cell count > 500 cells/mm3 who interrupted HAART.

(PDF emailed within 0-6 h: $19.90)

Accession: 012210822

Download citation: RISBibTeXText

PMID: 15650419

DOI: 10.1089/aid.2004.20.1283



Related references

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proceedings of the National Academy of Sciences of the United States of America 98(23): 13288-13293, 2001

Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. Journal of Acquired Immune Deficiency Syndromes 46(1): 39-47, 2007

Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. Journal of Virology 76(23): 12344-12348, December, 2002

Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center. Aids and Behavior 20(5): 1068-1075, 2015

Structured treatment interruptions in antiretroviral management of HIV-1. Current Opinion in Infectious Diseases 14(1): 29-37, 2002

Structured interruptions in antiretroviral treatment: a new therapeutic strategy?. Enfermedades Infecciosas Y Microbiologia Clinica 20(8): 373-375, 2002

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clinical Infectious Diseases 40(5): 728-734, 2005

Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. Journal of Infection 54(2): 159-166, 2006

Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. Journal of Infectious Diseases 197 Suppl 3: S261-S271, 2008

Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions. Aids 17(14): 2145-2146, 2003

CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antiviral Therapy 15(3): 351-361, 2010

Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. European Journal of Medical Research 10(2): 56-62, 2005

Prolonged and continuous treatment of SIVmac251 chronically infected macaques with IL-2 and antiretroviral therapy does not influence virological outcome after ART suspension. Journal of Medical Primatology 31(4-5): 300, August, 2002

Pegylated interferon alpha in patients treated from primary HIV infection prevents viral rebound during structured treatment interruptions of antiretroviral drugs. Journal of Interferon & Cytokine Research 22(Supplement 1): S-80, 2002

Treatment interruptions in HIV-infected subjects. Journal of Antimicrobial ChemoTherapy 58(3): 502-505, 2006